Relmada Therapeutics (RLMD) Enterprise Value Growth (5y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.90% |
| Dec 31, 2025 | 4.50% |
| Sep 30, 2025 | 35.37% |
| Jun 30, 2025 | 31.23% |
| Mar 31, 2025 | 25.12% |
| Dec 31, 2024 | 17.35% |
| Sep 30, 2024 | -47.13% |
| Jun 30, 2024 | -50.19% |
| Mar 31, 2024 | -109.87% |
| Dec 31, 2023 | -108.81% |
| Sep 30, 2023 | -160.40% |
| Jun 30, 2023 | -121.19% |
| Mar 31, 2023 | -98.87% |
| Dec 31, 2022 | -90.32% |
| Sep 30, 2022 | -108.40% |
| Jun 30, 2022 | -162.19% |
| Mar 31, 2022 | -140.25% |
| Dec 31, 2021 | -114.07% |
| Sep 30, 2021 | -69.90% |
| Jun 30, 2021 | -66.59% |
| Mar 31, 2021 | -55.36% |
| Dec 31, 2020 | -50.57% |
| Sep 30, 2020 | -45.07% |
| Jun 30, 2020 | -42.94% |
| Mar 31, 2020 | -33.64% |
| Dec 31, 2019 | -29.95% |
| Sep 30, 2019 | 22.12% |
| Jun 30, 2019 | 18.46% |
| Mar 31, 2019 | 3.54% |